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Background: Distal limb fracture in man can induce a complex regional pain syndrome (CRPS) with pain, warmth,
edema, and cutaneous inflammation. In the present study substance P (SP, Tac1−/−) and CGRP receptor (RAMP1−/−)
deficient mice were used to investigate the contribution of neuropeptide signaling to CRPS-like changes in a tibia
fracture mouse model. Wildtype, Tac1−/−, and RAMP1−/− mice underwent tibia fracture and casting for 3 weeks,
then the cast was removed and hindpaw mechanical allodynia, unweighting, warmth, and edema were tested over
time. Hindpaw skin was collected at 3 weeks post-fracture for immunoassay and femurs were collected for
micro-CT analysis.
Results: Wildtype mice developed hindpaw allodynia, unweighting, warmth, and edema at 3 weeks post-fracture,
but in the Tac1−/− fracture mice allodynia and unweighting were attenuated and there was no warmth and edema.
RAMP1−/− fracture mice had a similar presentation, except there was no reduction in hindpaw edema. Hindpaw
skin TNFα, IL-1β, IL-6 and NGF levels were up-regulated in wildtype fracture mice at 3 weeks post-fracture, but in
the Tac1−/− and RAMP1−/− fracture mice only IL-6 was increased. The epidermal keratinocytes were the cellular
source for these inflammatory mediators. An IL-6 receptor antagonist partially reversed post-fracture pain behaviors
in wildtype mice.
Conclusions: In conclusion, both SP and CGRP are critical neuropeptide mediators for the pain behaviors, vascular
abnormalities, and up-regulated innate immune responses observed in the fracture hindlimb. We postulate that the
residual pain behaviors observed in the Tac1−/− and RAMP1−/− fracture mice are attributable to the increased IL-6
levels observed in the hindpaw skin after fracture.
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Complex regional pain syndrome (CRPS) usually devel-
ops after a regional injury and presents with distal limb
nociceptive, vascular, and bone changes that exceed the
expected clinical course of the inciting injury in both
magnitude and duration, frequently resulting in signifi-
cant motor impairment and disability. CRPS symptoms
usually gradually improve over the first year after injury,
but persistent CRPS is a serious problem, resulting in
edema, pain, weakness, contractures, and bone loss. Over
80% of chronic CRPS patients are severely disabled [1].
The debate regarding the underlying mechanisms of
CRPS has been dynamic and controversial, and despite
extensive investigation, the pathophysiology of this con-
dition remains undefined and there is considerable dis-
agreement on whether any treatment for CRPS is effective
[2-5]. There is clearly a need for mechanism based effect-
ive and safe treatments for this debilitating complication
of injury.
Early CRPS clinical findings include vasodilatation,
redness, warmth, increased spontaneous protein extrava-
sation, edema, periarticular bone loss, pain, and allodynia
in the injured limb [6]. Population-based studies indicate
that distal limb fracture is the most common cause of
CRPS [7,8] and we have developed and characterized a
rat fracture CRPS model mimicking the clinical condi-
tion. After distal tibia fracture and cast immobilization
for 4 weeks the rats develop chronic unilateral hindlimb
warmth, edema, facilitated spontaneous protein extrava-
sation, periarticular osteoporosis, hindlimb unweighting,
and allodynia, changes paralleling those observed in
CRPS patients [9]. The vascular and nociceptive changes
characteristic of the early stages of CRPS suggest an in-
flammatory process, yet there is little evidence for an
immunocyte response in these patients [10-15]. Similarly,
in the rat CRPS model we observe no evidence of macro-
phage, T-cell, or neutrophil infiltration in the hindpaw
skin at 4 weeks post-fracture [16]. On the other hand,
there is compelling evidence that neurogenic inflamma-
tory responses are exaggerated in the CRPS limb and in
the rat fracture model.
Neurogenic inflammation is mediated by the de-
polarization of small sensory afferents in the skin, trig-
gering the release of substance P (SP) and calcitonin
gene-related peptide (CGRP), neurotransmitters that
activate their receptors in the dermal vasculature to in-
duce protein extravasation and vasodilatation. Electrically
evoked extravasation and vasodilatation responses are
enhanced in CRPS patients and when SP is microdialyzed
in the skin there is exaggerated protein extravasation,
direct evidence of facilitated neurogenic inflammatory
responses in CRPS [17,18]. Furthermore, serum levels of
SP and CGRP are elevated in CRPS patients [19-21].
Similarly, after tibia fracture in rats there is increased SPand CGRP expression in the sciatic nerve and in serum,
up-regulated SP NK1 receptor expression in the endo-
thelial cells and keratinocytes of the hindpaw skin, and
SP evoked extravasation and edema responses are
enhanced in the fracture hindlimb [22]. Treating fracture
rats with an SP NK1 receptor antagonist reduced hindlimb
allodynia, warmth, and edema, suggesting that exaggerated
SP signaling contributes to the development of CRPS-like
changes after fracture [9].
Inflammatory cytokine levels are up-regulated in CRPS
skin [23-25], and levels of interleukin 1b (IL-1b), inter-
leukin 6 (IL-6), tumor necrosis factor a (TNFa), and
nerve growth factor (NGF) are elevated in the hindpaw
skin keratinocytes of fracture rats [16,26-28]. Treating
fracture rats with the TNF inhibitor etanercept, the IL-1
receptor antagonist anakinra, or the anti-NGF antibody
tanezumab reduced hindpaw allodynia and unweighting
at 4 weeks post-fracture [26,27,29].
Collectively, these data support the hypothesis that
fracture causes exaggerated SP and CGRP signaling in
the skin, resulting in increased extravasation, edema,
warmth, and pain behavior. The aims of current study
were to develop a tibia fracture CRPS model in mice and
utilize this model in SP deficient (Tac1−/−) and in CGRP
receptor (RAMP1−/−) deficient mice to directly test the
hypothesis that neuropeptide signaling is required for
the development of the post-fracture innate immunity
responses contributing to the development of pain be-
havior in the fracture model.
Results
Characterizing the WT, Tac1−/−, and RAMP1−/− mice
In the intact unfractured mice there were no differences
between wildtype (WT), SP deficient (Tac1−/−), and
CGRP receptor deficient (RAMP1−/−) mice in terms of
hindpaw von Frey thresholds, weight bearing, hindpaw
temperature, or hindpaw thickness. Figure 1A illustrates
that the Tac1−/− mice yielded shorter PCR product (size
130 bp) on agarose gel, whereas WT mice yielded longer
product (180 bp). WT and RAMP1−/− mice yielded PCR
products of 108 and 240 bp, respectively (Figure 1B).
Western blot assay demonstrated a protein band at
60.5 kDa in WT mice that was absent in the RAMP1−/−
mice, confirming knockout of RAMP1 protein in trans-
genic mice (Figure 1C). To confirm functional inhibition
of SP signaling in the Tac1−/− mice, the sciatic nerve was
exposed and electrically stimulated for 5 minutes at
C-fiber intensities and Evans blue dye extravasation
was quantified in the hindpaw skin of WT, Tac1−/− and
RAMP1−/− mice. Electrically evoked extravasation was
reduced by 62% in the SP deficient mice (vs WTcontrols,
p < 0.01), but no loss of extravasation response was
observed in the RAMP1−/− mice (n = 6 per cohort,
Figure 1D).
Figure 1 Genotyping and phenotyping of substance P (SP)
deficient (Tac1−/−) and CGRP receptor deficient (RAMP1−/−)
mice. PCR products of tail DNA from wildtype (WT) and Tac1−/− mice
yielded 190 and 170-bp PCR fragments, respectively (A). The knockout
mutant PCR fragment was shorter due to the targeted deletion. WT
and mutant RAMP1−/− alleles yielded 108 and 240-bp PCR fragments,
respectively. Western blot assay was used to demonstrate that RAMP1
protein expression in the hindpaw skin was abolished due to
disruption in the genomic structure of the RAMP1 allele (C) Electrically
evoked extravasation responses were quantified by measuring Evans
blue dye content in the hindpaw skin after 5 minutes of sciatic
stimulation at C-fiber intensity (D). Tac1−/− mice extravasation
responses were reduced 60% vs WT mice, but no decrease in
extravasation was observed in the RAMP1−/− mice (n = 6 per cohort).
These results indicate that neuronal SP release can induce
microvascular protein extravasation into the cutaneous interstitial
space, but neuronal CGRP release is an ineffective mediator of
cutaneous extravasation. **P <0.01 vs WT, #P < 0.05 vs Tac1−/−.
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After baseline testing, 3 month-old male WT, Tac1−/−,
and RAMP1−/− mice (n = 10–12 per cohort) underwent
a right distal tibia fracture with 3 weeks cast im-
mobilization. Two additional groups of control mice
were used in these experiments, WT mice that had a
crush injury (no fracture) to the distal tibia using the
same hemostat used to fracture the tibia (WT Crush,
n = 8) and WT mice that underwent hindlimb cast
immobilization for 3 weeks with no fracture (WT Cast,
n = 8). Figures 2 A-E show that the WT crush mice
failed to develop any nociceptive or vascular changes,
but the 3 week cast immobilized control mice (WT Cast,
no fracture) did develop hindpaw von Frey allodynia and
unweighting, but not warmth and edema. Figure 2 illus-
trates that at 3 weeks post-fracture most of the WT
mice (n = 40) developed hindpaw allodynia (89.3%incidence, inclusion based on a minimum reduction of
at least 1.3 g in the von Frey hindpaw withdrawal
threshold, fracture vs contralateral side), hindpaw
unweighting (85% incidence, based on at least 30%
unweighting of the hindpaw, fracture vs contralateral
side), hindpaw warmth (80% incidence, based on a mini-
mum reduction in hindpaw skin temperature of 0.5°C,
fracture vs contralateral hindpaw), and hindpaw edema
(87.5% incidence, based on a minimum increase in hind-
paw thickness of 0.1 mm, fracture vs contralateral side).
Figures 2A and E illustrate that after cast removal both
the WT and the transgenic mice had developed reduced
withdrawal thresholds to von Frey testing, but the
Tac1−/− and RAMP1−/− mice had significantly less allo-
dynia than WT fracture mice. Similarly, at 3 weeks
post-fracture both the WT and the transgenic mice
unweighted the injured hindlimb, but both the Tac1−/−
and RAMP1−/− mice had significantly less hindpaw
unweighting than the WT mice (Figures 2B,F).
The WT mice also exhibited increased hindpaw
temperature and thickness at 3 weeks post-fracture, vs
the contralateral paw, but the SP deficient mice failed
to develop significant hindpaw warmth or edema
(Figures 2C,D). The RAMP1−/− fracture mice failed to
develop hindpaw warmth after fracture, but had a
similar degree of hindpaw edema as the WT fracture
mice (Figures 2G,H).
Figure 3 illustrates the time course for the resolution
of hindlimb allodynia, unweighting, warmth, and edema
after tibia fracture in WTand SP deficient mice. Hindpaw
von Frey allodynia resolved by 18 weeks post-fracture in
WT mice and by 6 weeks after fracture in the Tac1−/−
mice (Figure 3A). Hindlimb unweighting recovered by
10 weeks post-fracture in the WT mice and by 8 weeks
after fracture in the Tac1−/− mice (Figure 3B). Figure 3C
illustrates that temperature in the injured hindpaw
remained significant significantly elevated for 6 weeks
after fracture in the WT mice, but there was no
temperature increase at any time point in the SP deficient
mice. Hindpaw edema resolved by 6 weeks post-fracture
in the WT mice and no edema was observed at any time
point in the Tac1−/− mice (Figure 3D). There were no
contralateral effects of fracture on hindpaw temperature
or thickness at any time point in either mouse strain.
Effects of fracture on hindpaw skin cytokine and NGF
levels
The effects of fracture on hindpaw skin cytokine and
NGF levels were measured in unfractured and fractured
WT, Tac1−/−, and RAMP1−/− mice (n = 8 per group).
Hindpaw skin was collected the day after cast removal
(3 weeks post-fracture) and TNFα, IL-1β, IL-6, and NGF
protein levels were determined. Figure 4 illustrates that
there were no significant differences in basal TNFα,
Figure 2 (See legend on next page.)
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Figure 2 Wildtype (WT), substance P deficient (SP KO, Tac1-/-), and CGRP receptor deficient (RAMP1 KO, RAMP1-/-) mice underwent
behavioral testing and then distal tibia fracture (FX) with hindlimb casting for 3 weeks, then the cast was removed and behavioral
testing repeated (n = 10-12). Baselines did not differ between WT, SP KO, and RAMP1 KO mice. Controls included WT mice with no treatment
(WT Control), WT mice with crush injury (no FX) of the distal ankle (WT Crush), and WT mice with hindlimb casting (no FX) for 3 weeks (WT Cast).
WT Crush mice failed to develop nociceptive or vascular changes, but WT Cast mice developed hindpaw von Frey allodynia and unweighting,
but no warmth or edema (A-D). The absence of SP signaling (SP KO FX) partially inhibited post-FX allodynia (A) and unweighting (B) and
completely blocked warmth (C) and edema (D), compared to the WT FX mice. Similarly, the loss of CGRP signal (RAMP1 KO FX) partially inhibited
post-FX allodynia (E) and unweighting (F), completely blocked hindpaw warmth (G), and had no effect on hindpaw edema (H), compared to WT
fracture mice. For detailed descriptions of the hindpaw behavioral assays see Methods. A negative von Frey threshold value (A, E) represents
mechanical allodynia on the fracture side. A value less than 100% for weight bearing represents unweighting (B, F). Positive values for temperature
(C,G) or thickness (D,H) represent warmth or edema. * P < 0.05, **P < 0.01, and ***P < 0.001 vs WT Control, #P < 0.05, and ##P < 0.01 vs WT FX.
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RAMP1−/− unfractured control mice. Fracture caused a
dramatic increase in cytokine and NGF levels in WT
mice compared to unfractured WT controls. The SP
deficient mice had no significant changes in hindpaw
TNFα, IL-1β, and NGF levels after fracture, and the
post-fracture increase in IL-6 was significantly less than
the increase observed after fracture in the WT mice
(Figure 4A-D). A similar pattern was seen in RAMP−/−
fracture mice, with no significant increase in hindpaw
TNFα, IL-1β, and NGF levels after fracture, and the
post-fracture increase in IL6 was slightly greater thanFigure 3 After baseline testing, WT and SP KO (Tac1−/−) mice underw
for 3 weeks (black bar on x-axis), then the cast was removed and the
fracture (n = 7 per cohort). The methods for testing and calculating the g
present at 3 weeks in both groups and resolved by 18 weeks post-fracture
When compared at the same post-fracture time points the magnitude of a
the WT mice. (B) Hindpaw unweighting was present at 3 weeks after fractu
8 weeks the SP KO mice, but the magnitude of unweighting was consisten
edema (D) were present at 3 weeks post-fracture in the WT mice and reso
Hindpaw warmth and edema was not observed in the SP KO mice at any
same time point.the increase observed after fracture in the WT mice
(Figure 4E-H). These results indicate that SP and CGRP
signaling mediate the post-fracture up-regulation of
TNFα, IL-1β, and NGF expression, but not the increase
observed in IL-6 expression after fracture.
Cytokine induction in hindpaw skin keratinocytes after
tibia fracture
In this study we used confocal microscopy to determine
the cellular origin of the IL-1β and IL-6 cytokines in the
hindpaw skin after tibia fracture in the mouse. Skin sec-
tions were incubated with an antibody directed againstent a right distal tibia fracture (FX) and the hindlimb was casted
animals were retested at 3, 4, 6, 8, 10, 12, 15, and 18 weeks post
raph values are described in Figure 2. (A) Hindpaw allodynia was
in the WT mice and by 6 weeks post-fracture in the SP KO cohort.
llodynia was consistently less in the SP KO mice than that observed in
re in both groups and resolved by 10 weeks in the WT mice and by
tly less in the SP KO mice than the WT. Hindpaw warmth (C) and
lved by 8 weeks post-fracture for warmth and 6 weeks for edema.
time point. *P < 0.05, **P < 0.01, and ***P < 0.001 vs WT FX mice at the
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bodies against IL-1β or IL-6. Figure 5 shows that hind-
paw epidermal keratinocytes in WT control mice
expressed a low level of IL-1β and IL-6. In contrast,
robust IL-1β and IL6 staining was observed in keratino-
cytes throughout the epidermis in WT fracture mouse
hindpaw skin at 3 weeks post-fracture. These results in-
dicate that keratinocytes are the primary cellular source
of the up-regulated IL-1β and IL-6 cytokines observed in
hindpaw skin after fracture.
An IL-6 receptor antagonist reduced post-fracture pain
behavior in WT mice
When the IL-6 receptor antagonist TB-2-081 (2 mg/kg,
s.c.) was administered to WT fracture mice there was a
partial reduction in hindpaw allodynia and unweighting,
but no effect on hindpaw warmth or edema (Figure 6).
A lower dose of TB-2-081 (0.2 mg/kg, s.c.) had no
effect on allodynia or unweighting in the WT frac-
ture mice (data not shown). These results suggest that
the increased cutaneous IL-6 levels observed in the
Tac1−/− and RAMP1−/− fracture mice could be respon-
sible for the persistent von Frey allodynia and hindlimb
unweighting observed in the transgenic fracture mice.
Tibia fracture effects on trabecular and cortical bone
microarchitecture
MicroCT scanning was used to evaluate microarchitec-
ture in the bilateral femurs obtained from WT and
Tac1−/− mice at 3 weeks after tibia fracture (n = 10 per
cohort). The distal femur trabecular structural parameters
evaluated included bone volume fraction (BV/TV, %),
trabecular number (Tb.N, mm−1), trabecular thickness
(Tb.Th, μm), trabecular separation (Tb.Sp, μm), and con-
nectivity density (ConnD, mm−3). Cortical mid-femur
bone evaluation included the total cross-sectional area
(TtAr, mm2), cortical bone area (BAr, mm2), and the
bone area fraction (BAr/TtAr, %). There were no differ-
ences in the trabecular or cortical bone parameters of the
unfractured WT and Tac1−/− mice (Figure 7, Table 1).
Tibia fracture caused a 41% loss of distal femur trabecu-
lar bone volume ipsilateral to the fracture in wildtype
mice. Similarly, there was a 38% loss of distal femur bone
ipsilateral in the SP deficient mice (Figure 7A). Post-
fracture cortical bone area in the midfemur was also
reduced to an equal extent in the WT and Tac1−/− mice
(Figure 7B). Similarly, there were no significant differ-
ences between WT and Tac1−/− mice for fracture effects
on any other trabecular and cortical structural para-
meters evaluated in this study (Table 1).
Discussion
In this study we describe a novel mouse fracture model
that resembles CRPS in; 1) traumatic etiology and naturalhistory, 2) vascular changes, 3) mechanical sensitivity
and guarding, 4) up-regulation of cutaneous inflamma-
tory mediators, and 5) regional periarticular bone loss.
After a tibia fracture and 3 weeks cast immobilization
the WT mice developed chronic allodynia, unweighting,
warmth, and edema (Figure 2), and these vascular and
nociceptive changes gradually resolved over a period of
16 weeks (Figure 3).
In an earlier investigation we tested the hypothesis
that exaggerated neurogenic inflammatory responses
contribute to the vascular and nociceptive sequelae of
fracture in rats. When fracture rats were treated with a
single-dose of an SP NK1 receptor antagonist there was a
51% reduction in hindpaw spontaneous protein extrava-
sation, a 56% decrease in edema, and a 40% reduction in
von Frey fiber allodynia [9]. The results of the current
study confirm and extend these findings. SP deficient
(Tac1−/−) fracture mice had 54% less von Frey allodynia,
70% less hindpaw unweighting, and no hindpaw warmth
or edema, compared to WT fracture mice at 3 weeks
post-injury (Figure 2). Time-course studies demonstrated
further differences in the magnitude and duration of
post-fracture nociceptive behaviors in the WT and
Tac1−/− mice. The WT mice developed nociceptive beha-
viors persisting for 8–15 weeks after fracture, while in
the SP deficient mice nociceptive behaviors persisted for
only 4–6 weeks post-fracture (Figure 3). These data con-
firm that SP is a critical regulator for the development of
nociceptive and vascular sequelae after fracture. Simi-
larly, CGRP receptor deficient (RAMP1−/−) fracture mice
had attenuated allodynia and hindpaw unweighting, and
no hindpaw warmth, but post-fracture edema was not
affected by the loss of CGRP signaling (Figure 2). The
contribution of SP and CGRP signaling to post-fracture
hindpaw warmth and the essential role of SP signaling in
the development of post-fracture hindpaw edema corre-
lates with the results of intradermal microdialysis studies
in human subjects demonstrating that SP or CGRP perfu-
sion induces a vasodilation response in the skin, but only
SP perfusion can evoke a protein extravasation response
[30]. In addition, the sciatic nerve electrically evoked pro-
tein extravasation response was dramatically reduced in
Tac1−/− mice and unchanged in the RAMP1−/− mice
(Figure 1C), indicating that CGRP signaling does not
contribute to neurogenic extravasation in mice. Spontan-
eous protein extravasation is up-regulated in CRPS
affected limbs [31], leading to increased interstitial fluid
flow and distal limb edema, an important component of
CRPS [12].
When SP or CGRP is microdialyzed through the skin
of normal volunteers [30] or in CRPS skin [18] there is
no immediate painful response, leading us to postulate
that SP and CGRP act as intermediate mediators in the
development of post-traumatic pain. Increased levels of
Figure 4 Determination of hindpaw skin cytokine and NGF levels at 3 weeks after fracture (FX) in WT, SP deficient (SP KO, Tac1−/−),
and CGRP receptor deficient (RAMP1 KO, RAMP1−/−) mice. TNFα (A, E), IL-1β (B, F), IL-6 (C, G) and NGF (D, H) production in hindpaw
skin were determined by Bio-Rad bead suspension array (for cytokines) and EIA (for NGF). Baseline cytokine and NGF levels were the
same in all 3 groups of mice. Tibia fracture induced a significant increase in all three cytokine levels and NGF production in WT FX group vs WT
Controls, however, fracture did not induce increased TNFα (A), IL-1β (B), or NGF (D) levels in SP KO FX mice compared to unfractured SP KO
Control mice. The IL-6 (C) levels were elevated in the SP KO FX mice, compared to unfractured SP KO Control mice, but the IL-6 increase the SP
KO FX mice was considerable reduced compared to the IL-6 levels in the WT FX mice. A similar pattern was observed in the RAMP1 KO mice for
TNFα (E), IL-1β (F), or NGF (H), except the increase in IL-6 (G) levels in the RAMP1 KO FX mice was even greater than the increase observed in the
WT FX mice. Data are expressed as mean values (pg/mg protein) ± SE (n = 8 per group). *P < 0.05, **P < 0.001, and ***P < 0.0001 vs the respective
unfractured Control mice; #P < 0.05, ##P < 0.001, and ###P < 0.0001 vs WT FX mice.
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in experimental blister fluid or skin biopsies from the
affected, but not the contralateral limbs of CRPS
patients [23-25]. TNFα, IL-1b, IL-6, and NGF are up-
regulated in the hindpaw skin at 4 weeks after tibia
fracture in rats and fracture rats treated systemically
with the TNF inhibitor etanercept, the IL-1 receptor
antagonist anakinra, or the NGF antibody tanezumab
had reduced allodynia and hindlimb unweighting, indi-
cating an important role for cytokine and growth factor
signaling in the development of trauma induced chronic
pain [26,27,29].
The TNF, IL-1, and NGF inhibitors we have tested in
the fracture rat model are large molecules that can’t
cross the blood-brain barrier, suggesting that the pro-
nociceptive effects of these inflammatory mediators
probably occur at the nociceptor level in the sensitized
hindpaw skin. Pro-inflammatory cytokines and NGFcan immediately evoke spontaneous firing and sensi-
tization in primary sensory afferents [32-34]. Further-
more, we have observed that intraplantar injection of
these inflammatory mediators into normal hindpaw
skin rapidly induces nociceptive sensitization and have
identified keratinocytes as the primary cellular source
of these inflammatory mediators in the fracture hind-
paw (Figure 5) [28]. Robust keratinocyte proliferation
and epidermal thickening was also observed in the
fracture hindpaw [28]. Collectively, these data indicate
that up-regulated keratinocyte proliferation and/or in-
flammatory mediator expression results in increased cu-
taneous inflammatory mediator levels in the fracture
hindpaw, with subsequent nociceptive sensitization.
Neurotransmitter release evoked by capsaicin injection
or electrical nerve stimulation stimulates the production
of TNFα, IL-1β, IL-6, and NGF in the skin of rats, but it
is unknown which specific transmitters mediate these
Figure 5 Fluorescence photomicrographs of keratin (red), IL-1β (green), and IL-6 (green) immunostaining in the plantar hindpaw skin
at 3 weeks post-fracture (FX). The top two rows of panels show keratinocyte and IL-1β immunostaining from a wildtype (WT) unfractured
control (Cont) mouse (first row) and the second row panels are from a WT fracture mouse. The bottom two rows of panels show keratinocyte
and IL-6 immunostaining from a WT unfractured control mouse (third row) and the bottom row panels are from a WT fracture mouse. Double
labeling demonstrates fracture-induced IL-1β and IL-6 protein up-regulation localized within the epidermal keratinocyte layer of the WT mice.
Scale bar = 20 μm.
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observed that SP and CGRP signaling can stimulate
the secretion of IL-1β and NGF from keratinocyte cell
cultures, in vitro evidence that these neuropeptides can
directly stimulate keratinocyte inflammatory mediator
release [37-39].
Figure 4 illustrates the robust increase in TNFα, IL-1β,
IL-6, and NGF protein levels observed in the hindpaw
skin at 3 weeks post-fracture in the WT mice. Cytokines
are normally expressed transiently in response to injury
and infection and the persistent regional elevation of
cytokines observed at 3 weeks post-fracture indicates on-
going cytokine synthesis by the keratinocytes (Figure 5),
which we postulate is the result of exaggerated neuro-
peptide signaling. In support of this hypothesis, Tac1 orRAMP1 gene deletion prevented the up-regulation of
TNFα, IL-1β, and NGF in the injured hindlimb (Figure 4).
There were no differences between the WT, Tac1−/− and
RAMP1−/− mice in baseline cutaneous cytokine and NGF
levels, evidence that the low basal levels of cytokines and
NGF expressed in normal skin are not dependent on
neuropeptide signal.
Both the Tac1−/− and RAMP1−/− fracture mice had
increased IL-6 levels in the hindpaw skin, and there was
residual, albeit attenuated, allodynia and unweighting in
these transgenic fracture mice compared to WT fracture
mice (Figures 2,4). We postulated that IL-6 signaling
contributes to post-fracture allodynia and unweighting
and that the increase in skin IL-6 levels after fracture
in the Tac−/− and RAMP1−/− mice is the mechanism
Figure 6 After baseline testing, WT mice underwent a right distal tibia fracture (FX) and the hindlimb was casted for 3 weeks, then the
cast was removed and the next day the animals retested (n = 12 per cohort). Then the FX mice were either subcutaneously injected with
the IL-6 receptor antagonist TB-2-081 (FX + TB-2-081, n = 8) or vehicle (FX + Vehicle, n = 6). A control cohort of WT mice did not undergo tibia
fracture (Control, n = 12). At 15 minutes post-injection the mice were retested. The IL-6 receptor antagonist partially inhibited the development of
von Frey allodynia (A) and hindlimb unweighting (B) in the fracture mice, when compared to the extent of allodynia and unweighting observed
in the vehicle injected mice after fracture. The IL-6 receptor antagonist failed to reverse the hindpaw warmth (C) and edema (D) that was
observed in the vehicle injected fracture mice. ***P < 0.001 vs Control, ##P < 0.01, and ###P < 0.001 vs FX + Vehicle.
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unweighting observed in these strains. To test this
hypothesis we treated WT fracture mice with an IL-6
receptor antagonist (TB-2-081), and this treatment par-
tially reversed fracture-induced allodynia and unweight-
ing (Figure 6), supporting the hypothesis that increasedFigure 7 At 3 weeks after tibia fracture the wildtype (WT) and
substance P deficient (SP KO, Tac−/−) mice were euthanized and
the femurs ipsilateral to the fracture were collected for uCT
evaluation. No difference was observed in distal femur trabecular
bone volumes of WT and SP KO unfractured control mice (A), but
there was a dramatic post-fracture reduction in distal femur bone
volume in both strains of mice relative to their respective
unfractured controls (n = 10 per cohort). There was no difference in
the magnitude of post-fracture trabecular bone loss between WT
and SP deficient mice. Fracture also caused a slight reduction in
midfemur cortical bone area in both the WT and SP KO mice (B).
There were no differences between the WT and SP KO in either
baseline or post-fracture midfemur relative cortical areas.
###P < 0.001 vs respective unfractured controls.cutaneous IL-6 signal contributes to allodynia and
unweighting after fracture.
This study provides the first in vivo evidence that
SP and CGRP act as intermediate mediators in the
post-traumatic inflammatory cascade by chronically
up-regulating inflammatory proteins that can directly
sensitize cutaneous nociceptors. In contrast to other
inflammatory mediators examined in this study, the post-
fracture up-regulation of IL-6 did not require CGRP sig-
naling and was only partially dependent on SP signaling.
The significance of IL-6 signaling was confirmed by
antagonist studies demonstrating its role in the main-
tenance of post-fracture nociceptive behavior. Collectively,
these data suggest that neuronal regulation of innate
immunity can mediate inflammatory changes observed
in CRPS skin.
After tibia fracture WT mice developed trabecular,
and to a lesser extent cortical bone loss in the ipsilateral
femur when compared to unfractured controls (Figure 7,
Table 1). These data are consistent with the results
observed in the rat tibia fracture model [9], as well as in
CRPS patients who develop periarticular bone loss after
fracture [40]. The net effects of SP signaling on bone ac-
quisition and resorption in vivo are unknown, but previ-
ously we observed that the SP NK1 receptor is expressed
in both bone marrow stromal cells and bone marrow
macrophages and SP signaling stimulates bone marrow
stromal cell osteogenic activity as well as macrophage
osteoclast differentiation and resorption activity in vitro
[41]. The WT and SP deficient (Tac1−/−) mice had similar
baseline bone parameters and no post-fracture differ-
ences were observed in skeletal integrity between groups,
indicating that SP signaling does not regulate post-
traumatic bone loss in mice (Figure 7 and Table 1).
Table 1 μCT skeletal morphology of the ipsilateral femurs in the control and tibia fractured (FX) wild type and SP
deficient mice at 3 weeks post-injury
Wildtype mice SP deficient mice
Control FX MPD Control FX MPD
Distal femur
BV/TV (%) 22.8 ± 0.7 13.4 ± 0.8 −41.2%*** 22.3 ± 1.3 13.9 ± 0.5 −37.7%***
TbN (mm-1) 5.1 ± 0.1 4.6 ± 0.1 −9.8%*** 5.3 ± 0.1 4.7 ± 0.1 −11.3%***
TbTh (μm) 58.5 ± 0.5 47.6 ± 0.7 −18.6%*** 54.7 ± 1.6 46.6 ± 0.5 −14.8%***
TbSp (μm) 185 ± 3 209 ± 5 13.0%*** 177 ± 4 203 ± 3 14.7%***
ConnD (1/mm3) 156 ± 7 106 ± 8 −32.1%*** 181 ± 6 125 ± 5 −30.9%***
Middle femur
BAr (mm2) 1.04 ± 0.01 0.90 ± 0.02 13.5%*** 0.97 ± 0.04 0.85 ± 0.02 12.4%*
TtAr (mm2) 2.22 ± 0.04 2.22 ± 0.06 0 2.11 ± 0.07 2.12 ± 0.05 0.5%
MeAr (mm2) 1.18 ± 0.03 1.32 ± 0.06 11.9%* 1.14 ± 0.04 1.27 ± 0.04 11.4%*
CtTh (μm) 224 ± 2 189 ± 5 −15.6%*** 211 ± 5 185 ± 4 −12.3%***
BPm (mm) 9.9 ± 0.1 10.3 ± 0.2 4.0% 9.8 ± 0.2 10.0 ± 0.1 2.0%
BAr/TtAr (%) 47.0 ± 0.4 40.7 ± 1.1 13.4%*** 45.9 ± 0.4 40.3 ± 0.8 12.2%***
The changes of trabecular and cortical bone parameters in wild type and SP-deficient mice are expressed as the Mean Percent Difference (MPD).
MPD = ((FX - Control)/Control) × 100. Bold font indicates statistically significant differences in MPD between FX and age-matched controls for both wild type and
SP deficiency mice, as determined by Students’ t-test (mean ± SE, *p < 0.05, **p < 0.01 and ***p < 0.001).
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tenderness over the distal limb joints and pain with
range of motion [15,42]. It is unknown whether the neu-
roinflammatory changes observed in the fracture limb
skin may also be occurring in the joints or muscles of
the injured limb, but there are some intriguing clues.
The most prominent histological finding in CRPS syn-
ovial biopsies is the proliferation of synovial lining cells
[15]. Synoviocytes express NK1 receptors and very low
concentrations of SP can stimulate synoviocyte prolif-
eration in vitro [43,44]. Stimulated synoviocytes express
IL-6 and CCL2, a chemokine which induces monocytes
to leave the bloodstream and enter the surrounding tis-
sue to become synovial macrophages, the primary source
of TNFα and IL-1β in rheumatoid joints [45]. Examining
neuroinflammatory articular changes after fracture could
potentially identify signaling mechanisms contributing to
the articular tenderness and joint motion pain associated
with CRPS.
Conclusions
There have been numerous unsuccessful clinical trials
testing the analgesic efficacy of NK1 antagonists in post-
herpetic pain, diabetic neuropathy, osteoarthritis, and
migraine patients [46]. Only post-operative pain has
been responsive to NK1 antagonist analgesia in clinical
trials [47] and our previous work with the hindpaw inci-
sion post-operative pain model in SP deficient mice [48]
suggests that SP signaling contributes to both the post-
incision increase in inflammatory mediator levels in the
traumatized skin and the subsequent post-operative pain.We postulate that the mixed results of the NK1 antagonist
clinical trial data reflect differing pathophysiologic
mechanisms underlying the various pain etiologies exam-
ined in these trials. CGRP receptor antagonists have been
demonstrated to effectively reduce pain in migraine
patients but have not been tested in other types of pain
patients [49]. The results of the current study supports
the hypothesis that SP and CGRP signaling contribute to
the post-fracture up-regulation of cutaneous inflamma-
tory mediators capable of inducing pain behaviors in the
mouse CRPS model and these data provide a transla-
tional basis for future clinical trials with NK1 or CGRP
antagonists in early CRPS.
Methods
Study design
Baseline determinations were made of bilateral hind-
paw von Frey withdrawal thresholds, weight bearing,
temperature, and thickness in the wildtype (WT), SP
deficient (Tac1−/−), and CGRP receptor deficient
(RAMP1−/−) mice. Then the mice underwent a right distal
tibia fracture with cast immobilization for 3 weeks, then
the cast was removed and the mice were retested the
following day. One group of WT mice did not undergo
fracture and served as controls. Two groups of additional
groups of control mice were used in these experiments;
1) WT mice that had a crush injury (no fracture or cast)
to the distal tibia using the same hemostat used to frac-
ture the tibia, and 2) WT mice that underwent hindlimb
cast immobilization for 3 weeks with no fracture. After
behavioral testing the mice were euthanized and the
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other group of WT fracture mice underwent behavioral
testing the day after cast removal and the next day were
subcutaneously injected with either the IL-6 receptor an-
tagonist TB-2-081 [50] or vehicle (50% PBS/50%EtoH,
total volume 50 ul) and 15 min later behavioral testing
was repeated. Another group of WT and Tac1−/− fracture
mice underwent long-term behavioral testing over an 18-
week period after cast removal. Electrically evoked pro-
tein extravasation responses were evaluated in unfrac-
tured WT, Tac1−/−, and RAMP1−/− control mice to
confirm our hypothesis that the SP deficient mice had
impaired neurogenic extravasation and that RAMP−/−
mice had normal extravasation responses.
Mice
Mice that were homozygous for a disruption of the SP
expressing Tac1 (Tac1−/−) gene (B6.Cg-Tac1tm1Bbm/J)
and wildtype (WT) controls (C57Bl/6) were obtained
from Jackson Laboratory. CGRP receptor binding requires
the receptor activity-modifying protein 1 (RAMP1). Mice
that were homozygous for disruption of the RAMP1 gene
(RAMP1−/−) were generated by Dr Kazutake Tsujikawa
(Dept Immunology, Osaka University) on a C57Bl/6 back-
ground [51]. The Cre-loxP system was used to delete
exon 2 of the RAMP1 gene, with splicing of exons 1 to 3
creating a frameshift resulting in a termination codon at
the beginning of exon 3.
The genotype of each breeding pair was confirmed by
extracting DNA from tail snips and performing a PCR
assay using an Extract-N-AmpTM kit (XNAT-1KT,
Sigma). Forward (oIMR2033, 50-GCT CAT CAG TAT
GTG ACA TAG AAA) and reverse (oIMR2032, 50-AGA
ATT TAA AGC TCT TTT GCC) primers were used to
identify the Tac1−/− mice, based on the Jackson Labora-
tory’s genotyping protocol. The Tac1−/− mice yield
shorter PCR product (size 130 bp) on a 3% agrose gel,
whereas WT mice yielded longer product (180 bp).
Genotyping for the RAMP1−/− mice used a 50-specific
primer upstream of the 50 site in intron 1 (50-
CAGAATGGAGAAACTGAGTAGAGC-30), a 30-specific
primer immediately downstream of the first loxP site in
intron 1 (50-AGGAAGGAACGTAACACAGGTGG-30),
and a 30-specific primer downstream to the last loxP site
(50-GCTGTGCGTGGTGATGGAGG-30). The PCR reac-
tion conditions were: 40 cycles of a reaction consisting of
30 s of denaturation at 94°C, 30 s of annealing at 59°C,
and 60 s of elongation at 72°C [51]. Wildtype and
RAMP1−/− mice yielded PCR products of 108 and
240 bp, respectively.
The Tac1−/− mice are viable, fertile, normal in size and
do not display any gross physical or behavioral abnor-
malities [52]. SP is not immunodetectable in the Tac1−/−
mice and these mice have slightly reduced nociceptiveresponses to moderate/intense pain stimuli [52]. The
RAMP1−/− mice are also viable, fertile, normal in size,
and do no display any gross physical abnormalities [51].
The RAMP1−/− mice have hypertension without tachy-
cardia, exhibit no vasodilation response to intravenous
CGRP, and are incapable of nurturing their new born
pups, thus requiring surrogate mothers to raise their lit-
ters [51]. All experiments were done with the approval
of our Institutional Animal Care and Use Committee.Surgery
The fracture model was performed in 3 month-old male
mice. Under isoflurane anesthesia a hemostat was used
to make a closed fracture of the right tibia just distal to
the middle of the tibia. Then the hindlimb was wrapped
in casting tape (Delta-Lite) so the hip, knee and ankle
were all fixed. The cast extended from the metatarsals of
the hindpaw up to a spica formed around the abdomen.
A window was left open over the dorsal paw and ankle
to prevent constriction when post-fracture edema devel-
oped. After fracture and casting, the mice were given
subcutaneously 2 days of Buprenorphine (0.05 mg/kg)
and Baytril (5 mg/kg) as well as 1.5 ml of normal saline.
At 3 weeks after surgery the mice were anesthetized with
isoflurane and the cast removed. All mice had union at
the fracture site by manual inspection.Hindpaw hyperalgesia and unweighting
Mechanical allodynia was assayed using nylon von Frey
filaments according to the “up-down” algorithm as previ-
ously described [53]. The mice were placed on wire mesh
platforms in clear cylindrical plastic enclosures 10 cm in
diameter and 40 cm in height, and after 15 minutes of
acclimation von Frey fibers of sequentially increasing
stiffness were applied against the hindpaw plantar skin
at approximately midsole, taking care to avoid the tori
pads, and pressed upward to cause a slight bend in the
fiber and left in place for 5 sec. Withdrawal of or licking
the hindpaw after fiber application was scored as a
response. When no response was obtained the next
stiffest fiber in the series was applied to the same paw;
if a response was obtained a less stiff fiber was applied.
Testing proceeded in this manner until 4 fibers had been
applied after “negative + positive or positive + negative”
response. Estimation of the mechanical withdrawal thresh-
old by data fitting algorithm permitted the use of para-
metric statistics for analysis [54]. Baseline von Frey
withdrawal thresholds were identical in the WT, Tac1−/−,
and the RAMP1−/− mice.
An incapacitance device (IITC Inc) was used to
measure hindpaw unweighting. The mice were manually
held in a vertical position over the apparatus with the
hindpaws resting on separate metal scale plates and the
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paws. The duration of each measurement was 6 s and
6 consecutive measurements were taken at 10 s intervals.
All 6 readings were averaged to calculate the bilateral
hindpaw weight-bearing values.
Hindpaw volume
A laser sensor technique was used to determine the
dorsal–ventral thickness of the hindpaw, as we have
previously described [29]. The measurement sensor
device used in these experiments (Limab) has a measure-
ment range of 200 mm with a 0.01 mm resolution.
Hindpaw temperature
The temperature of the hindpaw was measured using a
fine wire thermocouple (Omega) applied to the paw
skin, as previously described previously [29]. The investi-
gator held the wire using an insulating Styrofoam block.
Three sites were tested over the dorsum of the hindpaw:
the space between the first and second metatarsals
(medial), the second and third metatarsals (central), and
the fourth and fifth metatarsals (lateral). After a site was
tested in one hindpaw the same site was immediately
tested in the contralateral hindpaw. The testing protocol
was medial dorsum right then left, central dorsum right
then left, lateral dorsum right then left, medial dorsum
left then right, central dorsum left then right, and lateral
dorsum left then right. The six measurements for each
hindpaw were averaged for the mean temperature.
Enzyme immunoassay for TNFα, IL-1β, IL-6 and NGF levels
in hindpaw skin
The mice were deeply anesthetized and bilateral dorsal
and plantar hindpaw skin were collected rapidly and
placed into ice cold 0.9% NaCl containing a cocktail of
protease inhibitors (Complete™, Roche Applied Science),
homogenized, then centrifuged (10 min, 12,000 G, 4°C),
then supernatant fractions were frozen at −80°C. An ali-
quot was subjected to protein assay (DC Protein Assay,
Bio-Rad) to normalize mediator levels. Cytokine protein
levels were determined using a custom Bio-Plex kit for
TNFα, IL-1β, and IL-6, analyzed on a Bio-Plex system
array reader (Bio-Rad) as previously described [55].
Samples were diluted 1:2 prior to analysis in the buffer
supplied, and all samples were run in duplicate for each
assay. We demonstrated previously that the dynamic
range of sensitivity of this assay was sufficient to measure
both baseline and incision-stimulated levels of the
chosen cytokines [55]. Standard curves for each of the
analyzed substances were included in each run, and
sample concentrations were calculated using Bio-Plex
Manager software. NGF levels were determined using
the ChemiKine EIA kit (Chemicon). Sample prepar-
ation was identical to that described for the cytokines.Western blot assay for RAMP1 protein levels in
hindpaw skin
Western blotting was carried out to confirm RAMP1
protein knockout in the RAMP1−/− mice. Hindpaw skin of
WT and RAMP1−/− mice was collected under isoflurane
anesthesia and homogenized in modified RIPA buffer
(50 mM Tris–HCl, 150 mM NaCl, 1 mMEDTA, 1% Igepal
CA-630, 0.1% SDS, 50 mM NaF, and 1 mM NaVO3) con-
taining protease inhibitors (aprotinin (2 μg/ml), leupeptin
(5 μg/ml), pepstatin (0.7 μg/ml), and PMSF (2 mM);
Sigma). The homogenate was centrifuged at 13,000 g for
30 min at 4°C. Total protein concentration of the hom-
ogenate was measured using a Coomassie Blue Protein
Assay (Bio-Rad) and BSA protein standard (Pierce). The
supernatant was subjected to western blot analysis. Equal
amounts of protein (50 μg) were subjected to SDS-PAGE
(12% Tris–HCl acrylamide gel, Bio-Rad) and electro-
transferred onto a polyvinylidene difluorided membrane
(Millipore). The blots were blocked with 5% non-fat dry
milk in tris-buffered saline, incubated with goat anti-
RAMP1 antibody (Novus Biologicals) overnight at 4°C
and further incubated with HRP-conjugated secondary
antibody (Santa Cruz Biotechnology) for 1 hr at room
temperature. After washing in TBST three times, the blot
was then incubated in ECL plus chemoluminescence
reagents (Amersham) and scanned by PhosphoImager
(Typhoon, GE Healthcare) to detect specific bands.
Immunofluorescence confocal microscopy
The mice were euthanized and perfused with 50 ml 4%
paraformaldehyde (PFA) in phosphate buffered saline,
pH 7.4, via the ascending aorta; the plantar hindpaw skin
including sub-dermal layers was removed and post-fixed
in 4% PFA for 2 hours, then the tissues were treated
with 30% sucrose in PBS at 4°C before embedding in
OCT. Following embedding, 8-μm thick slices were
made using a cryostat, mounted onto Superfrost micro-
scope slides (Fisher Scientific), and stored at −80°C. Fro-
zen sections were permeabilized and blocked with PBS
containing 10% donkey serum and 0.3% Triton X-100,
followed by exposure to the primary antibodies overnight
at 4°C in PBS containing 2% serum. Upon detection of
the first antigen, primary antibody from a different
species against the second antigen was applied to the
sections and visualized using an alternative fluorophore-
conjugated secondary antibody. Sections were then
rinsed in PBS and incubated with fluorophore-conjugated
secondary antibodies against the immunoglobulin of the
species from which the primary antibody was generated.
After three washes, the sections were mounted with
anti-fade mounting medium (Invitrogen). Images were
obtained using a confocal microscope (Zeiss LSM/510
Upright 2 photon; Carl Zeiss) and stored on digital
media.
Guo et al. Molecular Pain 2012, 8:85 Page 13 of 15
http://www.molecularpain.com/content/8/1/85For IL-6 immunostaining rabbit anti human IL-6 anti-
body (1:400, LifeSpan Biosciences Inc) was labeled with
donkey anti-rabbit IgG (1:500) conjugated with Dylight
488 secondary antibodies (Jackson ImmunoResearch).
Control experiments included incubation of slices in pri-
mary and secondary antibody-free solutions both of
which led to low intensity non-specific staining patterns
in preliminary experiments. For the detection of epider-
mal keratinocytes, rabbit anti keratin 14 polyclonal anti-
body (Convance Inc) was labeled with Alexa Fluor 555
microscale protein labeling kit (Invitrogen Molecular
Probes) under optimum conditions according to the
manufacture’s protocol, and quantified using a NanoDrop
ND-1000 UV–vis spectrophotometer (NanoDrop Tech-
nologies), the concentration of purified protein conjugate
was 0.34 mg/ml. Then an equal volume of glycerol (ACS
grade) was added for a final concentration of 50%. Upon
detection of the IL-6 as described above, 250 μl of a
1:200 dilution of the conjugate was used for the keratin
14 immunostaining. Control experiments included incu-
bation of slices in primary and secondary antibody-free
solutions both of which led to low intensity non-specific
staining patterns in preliminary experiments.
For IL1-b immunostaining, the primary antibodies,
rabbit anti-mouse IL-1b, 1:200 (Millipore) and mouse
monoclonal antibody to Pan Keratin, 1:50 (Abcam) were
used. Double labeling immunofluorescence was performed
with donkey anti-mouse IgG (1:500) conjugated with
Dylight 549, donkey anti-rabbit IgG (1:500) conjugated
with Dylight 488 secondary antibodies (Jackson Immu-
noResearch), incubated with respective primary anti-
bodies. Control experiments included incubation of
slices in primary and secondary antibody-free solutions
both of which led to low intensity non-specific staining
patterns in preliminary experiments.
Electrical stimulation-evoked extravasation procedure
Under isoflurane anesthesia both sciatic nerves were
exposed in the thigh and tightly ligated proximal to
the midthigh stimulation site. Then the incision was
filled with warm mineral oil and a Plexiglas-platinum
stimulating electrode was gently secured around the
nerve (Harvard Apparatus). Evans blue dye (25 mg/kg,
Sigma) dissolved in saline was administered through
the jugular vein, and 10 minutes later bilateral sciatic
nerves were stimulated for 5 min (5 Hz, 0.5-ms pulse
duration, 10 mA) and then the mice were transcar-
dially perfused with 30 ml normal saline. The plantar
and dorsal skin on each hindpaw was excised and then
placed in 1 ml of formamide in a shaker bath at 55°C
for 72 h. The extracted dye concentration was deter-
mined with a spectrophotometer at 620 nm. Because
Evans blue binds to serum albumin, the dye content of
the hindpaw skin provides an accurate measure ofelectrically evoked protein extravasation into the inter-
stitial space.Microcomputed tomography (μCT)
To assess trabecular and cortical bone architecture,
ex vivo scanning was performed using μCT (VivaCT 40,
Scanco Medical AG) as we have previously described
[27]. In the distal femur, 160 transverse slices of 10.5 μm
thickness (10.5-μm isotropic voxel size) encompassing a
length of 1.68 mm were acquired, but only 100 slices
encompassing 1 mm in the distal femur were evaluated,
starting where the growth plate bridge across the middle
of the metaphysis ends. The region of interest (ROI) was
manually outlined on each CT slice, excluding the pri-
mary spongiosa, and extending distally from the growth
plate. Image threshold was set by using an adaptive-
iterative algorithm for trabecular bone. Scan parameters
of threshold = 252, sigma = 0.8, support = 1 for proximal
tibia were used to measure trabecular bone volume frac-
tion (BV/TV, %), trabecular number (Tb.N, mm−1), tra-
becular thickness (Tb.Th, μm), trabecular separation (Tb.
Sp, μm), and connectivity density (ConnD, mm−3) [56,57].
For the mid-femur cortical bone evaluation, a total of
26 transverse CT slices were obtained at the mid-femur,
each 21 μm thick totaling 0.546 mm in length (21 μm
isotropic voxel size). Scan parameters of threshold = 350,
sigma = 1.2, and support = 1 were used to measure total
cross-sectional area (Tt.Ar, mm2), cortical bone area
(B.Ar, mm2), cortical thickness (Ct.Th, μm), medullary
area (Me.Ar, mm2), and bone perimeter (B.Pm, mm).
Relative cortical bone area (B.Ar/T.Ar, %) was calculated.Statistical analysis
A two-tailed Student’s t-test was used to analyze differ-
ences between groups. A two-way repeated measures
ANOVA was used to analyze nociceptive and vascular
behavioral data for differences between groups over time.
All data were presented as the mean ± standard error of
the mean, and differences were considered significant at
a P value less than 0.05. Hindpaw temperature, thickness,
and mechanical nociceptive thresholds data were ana-
lyzed as the difference between the fracture side (right)
and the contralateral (left) side. Hindpaw weight bearing
data was analyzed as a ratio between the right hindpaw
weight and the sum of right and left hindpaws values
((2R/(R + L)) × 100%).
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